CBLL1

Across TCGA pan-cancer cohorts, CBLL1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CBLL1 data layer compared with 31 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CBLL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBLL1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

STAD, BLCA, and LIHC are the cancer types where CBLL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.074	0.667	<.001	30	view →
BLCA	DFS	Median	All	1.000	0.329	.020	28	view →
LIHC	DFS	Median	All	0.076	0.544	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.829	.021	12	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
LGG	DFS	Median	All	0.185	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CBLL1–STAD (OS)

Open the STAD breakdown →